)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Arctic Bioscience
Arctic Bioscience (ABS) investor relations material
Arctic Bioscience H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary27 Aug, 2026
Executive summary
Achieved 35.2% year-over-year Nutra revenue growth in H1 2026, with NOK 23.3m versus NOK 17.2m in H1 2025; US market revenue up 87% and now the largest segment.
Robust order pipeline and recurring customers underpin continued growth, with delayed H1 shipments completed early Q3.
Secured NOK 15m long-term loan, strengthening liquidity and supporting ongoing operations.
Advanced HR0350 psoriasis drug candidate with positive phase IIb data, ongoing phase III planning, and peer-reviewed publications.
Improved adjusted EBITDA to NOK -12.1m from NOK -13.6m year-over-year, reflecting cost control and operational efficiencies.
Financial highlights
Total revenue for H1 2026 reached NOK 25.0m, with sales revenue at NOK 23.3m, up 35.2% year-over-year.
Gross margin for H1 2026 was 29.8%, down from 33.4% in H1 2025.
EBITDA and adjusted EBITDA both at NOK -12.1m, reflecting ongoing investment in pharma development.
Net loss for H1 2026 was NOK -18.0m, a slight improvement from NOK -18.9m in H1 2025.
Available liquidity at period end was NOK 1.2m, supported by new long-term funding; equity ratio at 54%.
Outlook and guidance
Positive growth outlook for Nutra, with US and APAC regions prioritized for expansion.
China partnership signals further H2 2026 growth; robust order pipeline and recurring customers expected to drive results.
Pharma development to be financed separately; focus on advancing HR0350 to Phase III and securing partnerships.
Additional HR0350 clinical data to be published in H2 2026; ongoing evaluation of further financing initiatives.
Near-term priorities include delivering H2 orders, protecting margins, and maintaining liquidity discipline.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Arctic Bioscience
- Clinical progress and nutraceutical growth offset by ongoing losses and liquidity risks.ABS
H2 2025 - Q1 2026 revenue rose 78% with margin gains, strong Nutra growth, and HRO350 clinical progress.ABSQ1 2026 TU
- Nutraceutical revenues surged in Q3 2024, but further funding is needed for clinical progress.ABSQ3 2024 TU
- Record sales and clinical progress in 2024, but liquidity risk persists.ABSH2 2024
- 2025 sales and EBITDA improved, with strong 2026 outlook and pharma project progress.ABSQ4 2025 TU
- Clinical progress and cost cuts offset recall-driven revenue and margin declines.ABSQ3 2025 TU
- Improved margins, cost reductions, new funding, and promising clinical results marked H1 2025.ABSH1 2025
- Promising efficacy and robust safety for HRO350 in psoriasis, with key subgroup benefits.ABSStudy result
- Record sales, margin gains, and new funding support growth and positive cash flow targets.ABSQ4 2024 TU
Next Arctic Bioscience earnings date
Q3 2026 TU11 Nov, 2026
Arctic Bioscience
Next Arctic Bioscience earnings date
Q3 2026 TU11 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Arctic Bioscience ASA is a biotechnology company specializing in the development and production of health products derived from marine ingredients, particularly omega-3 fatty acids from herring roe. The company's products are used in the nutraceutical and pharmaceutical sectors, offering health benefits related to brain, heart, and immune function. In addition to producing omega-3-based supplements for consumer markets, Arctic Bioscience is involved in the research and development of new pharmaceutical applications utilizing marine-based bioactive compounds. The company is headquartered in Ørsta, Norway, and its shares are listed on the Oslo Stock Exchange.